Drugs / Hemay102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03982303 | Jan 2019 → Dec 2021 | — | Tianjin Hemay Oncology Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemay102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03982303 ↗ |
| Route | Intravenous | “Hemay102 was administered through i.v. infusion for 4hrs.” NCT03982303 ↗ |